JP2024518539A5 - - Google Patents
Info
- Publication number
- JP2024518539A5 JP2024518539A5 JP2023570121A JP2023570121A JP2024518539A5 JP 2024518539 A5 JP2024518539 A5 JP 2024518539A5 JP 2023570121 A JP2023570121 A JP 2023570121A JP 2023570121 A JP2023570121 A JP 2023570121A JP 2024518539 A5 JP2024518539 A5 JP 2024518539A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- group
- complex according
- polypeptide complex
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327317P | 2020-04-04 | 2020-04-04 | |
| US202163187690P | 2021-05-12 | 2021-05-12 | |
| US63/187,690 | 2021-05-12 | ||
| US63/327,317 | 2022-04-04 | ||
| PCT/US2022/027688 WO2022240637A2 (en) | 2020-04-04 | 2022-05-04 | Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518539A JP2024518539A (ja) | 2024-05-01 |
| JP2024518539A5 true JP2024518539A5 (enExample) | 2025-05-08 |
Family
ID=84029363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570121A Pending JP2024518539A (ja) | 2020-04-04 | 2022-05-04 | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12161724B2 (enExample) |
| EP (1) | EP4337697A4 (enExample) |
| JP (1) | JP2024518539A (enExample) |
| KR (1) | KR20240035392A (enExample) |
| CN (1) | CN117642156A (enExample) |
| AR (1) | AR125758A1 (enExample) |
| AU (1) | AU2022272906A1 (enExample) |
| BR (1) | BR112023023650A2 (enExample) |
| CA (1) | CA3218661A1 (enExample) |
| MX (1) | MX2023013382A (enExample) |
| TW (1) | TW202311289A (enExample) |
| WO (1) | WO2022240637A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013382A (es) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| US20240043536A1 (en) * | 2020-12-08 | 2024-02-08 | Janux Therapeutics, Inc. | Peptide compositions and methods for anti-cd3 binding domains |
| WO2025195306A1 (en) * | 2024-03-16 | 2025-09-25 | Vibrant Pharma Limited | Multispecific antigen-binding proteins and uses thereof |
| WO2025201240A1 (en) * | 2024-03-25 | 2025-10-02 | Tavotek Biotherapeutics (Hong Kong) Limited | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof |
| WO2025201560A1 (en) * | 2024-03-29 | 2025-10-02 | Vibrant Pharma Limited | Multispecific antigen-binding proteins and uses thereof |
| WO2026067689A1 (zh) * | 2024-09-28 | 2026-04-02 | 浙江道尔生物科技有限公司 | 肿瘤特异性激活的蛋白药物及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| CA2777825A1 (en) | 2009-10-28 | 2011-05-19 | Abbott Biotherapeutics Corp. | Anti-egfr antibodies and their uses |
| ES2993140T3 (en) | 2010-04-02 | 2024-12-23 | Amunix Pharmaceuticals Inc | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| CN103068847B (zh) * | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| CN103382223B (zh) | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| JP6509724B2 (ja) | 2012-04-20 | 2019-05-08 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| CN110078827A (zh) * | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| JP6092649B2 (ja) | 2013-02-15 | 2017-03-08 | キヤノン株式会社 | 演算装置、アレイ型演算装置およびその制御方法、情報処理システム |
| WO2015066279A2 (en) * | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| JP2016538275A (ja) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| CN105820248A (zh) | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3322735A4 (en) | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
| CN116333130A (zh) | 2016-05-24 | 2023-06-27 | 英斯梅德股份有限公司 | 抗体及其制备方法 |
| WO2019067015A1 (en) * | 2017-09-29 | 2019-04-04 | City Of Hope | RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA |
| JP2022535924A (ja) | 2019-06-06 | 2022-08-10 | ジャナックス セラピューティクス，インク． | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
| MX2021015882A (es) | 2019-06-26 | 2022-04-18 | Amunix Pharmaceuticals Inc | Fragmentos de unión a antígeno egfr y composiciones que los comprenden. |
| CA3143519A1 (en) | 2019-06-26 | 2020-12-30 | Volker Schellenberger | Cd3 antigen binding fragments and compositions comprising same |
| KR20210043475A (ko) | 2019-10-10 | 2021-04-21 | 주식회사 와이바이오로직스 | 다중 특이적 융합 단백질 및 이의 용도 |
| MX2023013382A (es) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| EP4631977A3 (en) | 2020-08-11 | 2025-12-10 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| WO2022094299A2 (en) | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| US20240043536A1 (en) | 2020-12-08 | 2024-02-08 | Janux Therapeutics, Inc. | Peptide compositions and methods for anti-cd3 binding domains |
| US20240254241A1 (en) | 2021-05-11 | 2024-08-01 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| EP4615514A2 (en) | 2022-11-10 | 2025-09-17 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| WO2024100451A2 (en) | 2022-11-11 | 2024-05-16 | Janux Therapeutics, Inc. | Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens |
-
2022
- 2022-05-04 MX MX2023013382A patent/MX2023013382A/es unknown
- 2022-05-04 TW TW111116883A patent/TW202311289A/zh unknown
- 2022-05-04 BR BR112023023650A patent/BR112023023650A2/pt unknown
- 2022-05-04 WO PCT/US2022/027688 patent/WO2022240637A2/en not_active Ceased
- 2022-05-04 JP JP2023570121A patent/JP2024518539A/ja active Pending
- 2022-05-04 KR KR1020237042777A patent/KR20240035392A/ko active Pending
- 2022-05-04 AU AU2022272906A patent/AU2022272906A1/en active Pending
- 2022-05-04 AR ARP220101168A patent/AR125758A1/es unknown
- 2022-05-04 US US18/559,201 patent/US12161724B2/en active Active
- 2022-05-04 EP EP22808066.9A patent/EP4337697A4/en active Pending
- 2022-05-04 CN CN202280049696.XA patent/CN117642156A/zh active Pending
- 2022-05-04 CA CA3218661A patent/CA3218661A1/en active Pending
-
2024
- 2024-10-17 US US18/919,094 patent/US12433953B2/en active Active
-
2025
- 2025-09-12 US US19/327,021 patent/US20260014267A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518539A5 (enExample) | ||
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| JP2023552812A5 (enExample) | ||
| JP2024510098A5 (enExample) | ||
| JP2022535924A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| US10738103B2 (en) | Antibody light chains | |
| JP2021502984A (ja) | Ｆｘ活性化を促進する第ｘ因子結合剤 | |
| Tillib | “Camel nanoantibody” is an efficient tool for research, diagnostics and therapy | |
| JP2005528914A5 (enExample) | ||
| JP2020531430A (ja) | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 | |
| JP2020515277A5 (enExample) | ||
| JP2024507540A5 (enExample) | ||
| JP2023552462A5 (enExample) | ||
| JP2022500455A5 (enExample) | ||
| JP2021506310A5 (enExample) | ||
| US20240019424A1 (en) | Method for resolving complex, multistep antibody interactions | |
| TWI789399B (zh) | 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途 | |
| CN121866271A (zh) | 靶向表皮生长因子受体的组合物及其制备和使用方法 | |
| CN113544157B (zh) | 用于检测或捕获样品中的多肽的抗体和组合物，以及用于检测或捕获样品中的多肽的方法 | |
| JP2025513930A5 (enExample) | ||
| JPWO2020071554A5 (enExample) | ||
| CN110172100A (zh) | 抗人cd3e抗体及其用途 | |
| US20230227536A1 (en) | Immunogenicity-reduced low-molecular antibody and method for producing same |